Guarded optimistic expectations are that seminal events can occur in the next 2–3 years: Such as Phase II survival benefit data for HER2/EGFR-targeting bispecific antibodies (e.g., AFM24), Phase III data for a universal iPSC-NK vaccine combined with a PD-1 inhibitor, and conditional approval for the first solid tumor indication (e.g., glioblastoma DC vaccine). The gene discussed is EGFR; the disease is glioblastoma.